Corvus Pharmaceuticals Inc (NASDAQ:CRVS) reported its second-quarter 2025 financial results, with a narrower-than-expected loss per share, prompting a positive after-hours market reaction. The company posted a loss of $0.10 per share, beating analyst estimates of a $0.14 loss. Revenue for the quarter came in at $0.0, in line with expectations.
Key Financial Highlights
- Earnings Per Share (EPS): Reported at -$0.10, surpassing the consensus estimate of -$0.14.
- Revenue: Remained at $0.0, matching projections, as the company has no commercialized products yet.
- Market Reaction: Shares rose ~5.8% in after-hours trading, reflecting investor optimism over the improved earnings performance.
Clinical Progress and Business Update
The earnings release highlighted promising data from the Phase 1 clinical trial of soquelitinib, Corvus’s lead candidate for atopic dermatitis. Key takeaways from the trial include:
- Earlier and deeper responses in cohort 3 compared to earlier cohorts.
- Clinically meaningful reduction in itch observed as early as day 8.
- Continued progress in evaluating ITK inhibition as a novel immunotherapy approach for autoimmune and oncological conditions.
While the company did not provide a formal financial outlook in the press release, analysts currently estimate:
- Q3 2025 EPS: -$0.15 (vs. Q2’s -$0.10).
- Full-year 2025 EPS: -$0.34, with no expected revenue.
Market Performance Context
Despite the post-earnings uptick, CRVS has seen mixed performance in recent weeks:
- Last week: -4.8%
- Last two weeks: -10.7%
- Last month: Flat (-0.2%)
The after-hours surge suggests that investors are encouraged by the narrower loss and positive clinical developments, though long-term sentiment will depend on further trial progress and eventual commercialization prospects.
For more detailed earnings estimates and historical performance, see Corvus Pharmaceuticals’ earnings data.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
